Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer

NCT05148546 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Neoadjuvant nivolumab
DRUG: Neoadjuvant ipilimumab
DRUG: Neoadjuvant relatlimab

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]